Home » Stocks » Lantern Pharma

Lantern Pharma, Inc. (LTRN)

Stock Price: $13.13 USD 0.18 (1.39%)
Updated Jul 2, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 81.64M
Revenue (ttm) n/a
Net Income (ttm) n/a
Shares Out 6.22M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Jul 2, 2020
Last Price $13.13
Previous Close $12.95
Change ($) 0.18
Change (%) 1.39%
Day's Open 13.01
Day's Range 12.97 - 13.30
Day's Volume 9,539
52-Week Range 11.51 - 15.44

More Stats

Market Cap 81.64M
Enterprise Value 81.06M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 6.22M
Float 1.52M
EPS (basic) n/a
EPS (diluted) n/a
FCF / Share n/a
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 26,912
Short Ratio 0.05
Short % of Float 1.17%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 133.78
Revenue n/a
Operating Income n/a
Net Income n/a
Free Cash Flow n/a
Net Cash 580,982
Net Cash / Share 0.09
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA n/a
ROE n/a
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

*No analysts have provided price targets for this stock.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Operating Income-2.43-1.73
Net Income-2.43-1.73
Shares Outstanding1.141.11
Earnings Per Share-2.14-1.56
Cash & Equivalents1.230.45
Net Cash / Debt1.230.45
Book Value0.94-0.20
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Lantern Pharma, Inc.
Country United States
Employees 4
CEO Panna L. Sharma

Stock Information

Ticker Symbol LTRN
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: LTRN
IPO Date June 11, 2020


Lantern Pharma Inc., a clinical stage biotechnology company, focuses on leveraging artificial intelligence (A.I.), machine learning, and genomic data to streamline the drug development process. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, prostate cancer. The company also develops LP-300 as a combination therapy for female non or never-smokers with non-small cell lung cancer adenocarcinoma. In addition, its preclinical development drug candidate is LP-184, a non-hormone, non-chemotherapy, next generation alkylating agent with nanomolar potency that damages DNA in cancer cells that overexpress certain biomarkers indicated primarily in solid tumors, such as those in prostate and ovarian cancers. The company was incorporated in 2013 and is based in Dallas, Texas.